KEY INVESTOR INFORMATION

This document provides you with key investor information about this Fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this Fund. You are advised to read it so you can make an informed decision about whether to invest.

VanEck Medical Robotics and Bionic Engineering UCITS ETF (the "Fund")

a sub-fund of VanEck UCITS ETFs plc (the "Company")
ISIN: IE0005TF96I9

This Fund is managed by VanEck Asset Management B.V., a subsidiary of Van Eck Associates Corporation.

Objectives and Investment Policy

The Fund's investment objective is to replicate, before fees and expenses, the MVIS® Global Bionic Healthcare ESG Index (the "Index").
In order to seek to achieve its investment objective, the Manager will normally use a replication strategy by investing directly in the underlying equity securities of the Index being stock, American depository receipts (ADRs), and global depository receipts (GDRs) that consists of the component securities of the Index. Such equity securities which form part of the Index are required to be issued by companies who generate at least 50% (25% for current components) of their revenues from medical, dental or vision-related implants, bioprinting, prosthesis, preservation of organs and tissue, and/ or medical robotics. This does not include companies involved in implantable wearable devices or materials used only for cosmetic purposes. Such equity securities must be listed or traded on the Markets referred to in Appendix II of the Prospectus.
The Manager has categorised the Product as meeting the provisions set out in Article 9(1) of Regulation (EU) 2019/2088 on sustainability related disclosures in the financial services sector ("SFDR") for products, which have sustainable investment as their objective and where an index has been designated as a reference benchmark. The Index considers ESG factors as further detailed in the Index methodology available on the Index Provider's website and in the Prospectus.
Where it is not practical or cost efficient for the Fund to fully replicate the Index, the Manager may utilise an optimised sampling methodology.
The Fund may also (or alternatively) invest in financial derivative instruments (FDIs) which relate to the Index or constituents of the Index.
The Fund may invest up to 15% of its Net Asset Value directly in shares issued by companies listed on the Shanghai Stock Exchange or the Shenzhen Stock Exchange. The Fund may invest more than 20% of its Net Asset Value in emerging markets.
The FDIs which the Fund may use are futures, options (puts and calls), swaps (including equity swaps and swaps on the Index), currency forwards and non-deliverable forwards (a forward contract that does not require settlement on maturity) (NDFs). The Fund may also invest in ancillary liquid assets and money market instruments which may include bank deposits, depositary receipts, certificates of deposit, fixed or floating rate instruments (treasury bills), commercial paper, floating rate notes and freely transferable promissory notes. The ancillary liquid assets, money market instruments and FDI (other than permitted unlisted investments) will be listed or traded on the Markets referred to in Appendix II of the Prospectus. The Fund invests in the underlying (physical) securities that make up the Index and does not take part in securities lending. The Fund may not invest more than 10% of its Net Asset Value in open-ended collective investment.
Furthermore, the Fund may not invest less than 51% of its Net Asset Value in equity securities which constitute "equity participation" within the meaning of section 2, Article 8 of the German Investment Tax Act.

The Fund, using a "passive" or indexing investment approach, attempts to approximate the investment performance of the Index by investing in a portfolio of securities that generally replicates the Index. The Manager will regularly monitor the Fund's tracking accuracy.
Recommendation: This Fund may not be appropriate for investors who plan to withdraw their money within 5 years.
• Fund's base currency: U.S. Dollar
• Distribution policy: Income accumulated
The shares are admitted for trading on various stock exchanges and can be traded on the secondary market. The price of the shares offered on the secondary market may deviate from the net asset value of the shares. The return of the Fund is directly related to the return of the underlying assets minus the costs associated with the Fund. If the performance of the underlying assets decreases, the performance of the Fund will also decrease. There is no capital protection against Market Risk.

Risk and Reward Profile

Lower risk — **Higher risk**
Typically lower reward — **Typically higher reward**

1	2	3	4	5	**6**	7

The risk and reward indicator is calculated using historical and simulated historical data. Historical data may not be a reliable indication for the future. Therefore, the risk classification may change over time.

Even if the Fund is in the lowest risk category, it does not mean it is risk free or that capital is guaranteed or protected.

This Fund is ranked at 6 because funds of this type have experienced very high rises and falls in value in the past.

The following risks can be materially relevant but are not necessarily adequately captured by the synthetic risk indicator and may cause additional loss:

- Liquidity Risks: Exists when a particular financial instrument is difficult to purchase or sell. If the relevant market is illiquid, it may not be possible to initiate a transaction or liquidate a position at an advantageous or reasonable price, or at all.
- Equity Market Risk: The prices of the securities in the Fund are subject to the risks associated with investing in the securities market, including general economic conditions and sudden and unpredictable drops in value. An investment in the Fund may lose money.
- Industry or Sector Concentration Risk: The Fund's assets may be concentrated in one or more particular sectors or industries. The Fund may be subject to the risk that economic, political or other conditions that have a negative effect on the relevant sectors or industries will negatively impact the Fund's performance to a greater extent than if the Fund's assets were invested in a wider variety of sectors or industries.

For more information on risks, please see the "Risk Factors" section of the Fund's prospectus, available on www.vaneck.com.

Charges

The charges you pay are used to pay the costs of running the Fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

One-off charges taken before or after you invest	
Entry charge	None*
Exit charge	None*

These are the maximum charges that could be taken from your money before it is invested or before we pay out the sale proceeds of your investment.

Charges taken from the Fund over a year	
Ongoing charges	0.55%

Charges taken from the Fund under certain specific conditions	
Performance fee	None

*Not applicable to investors on the secondary market. Investors who buy or sell shares via a market pay the costs charged by their financial intermediaries. Information on these charges can be obtained from the markets where the shares are listed and traded or from the financial intermediaries.

You can find more information on the charges in the cost section of the Fund's prospectus and/or supplement. This is available at www.vaneck.com.

The ongoing charges figure is based on expenses for the 12-month period ending 31 December 2025. This figure may vary from year to year. It excludes portfolio transaction costs.

Past Performance



Any indication of past performance is not a reliable indicator of future performance.

*Effective September 19, 2025 the Fund's investment objective has been amended to include medical robotics.

The chart shows the Fund's annual performance in USD for each full calendar year over the period displayed in the chart. It is expressed as a percentage change of the Fund's net asset value at each year-end. The Fund was launched on 02 December 2022.

Performance is shown after deduction of ongoing charges.

Practical Information

The Depositary of the Fund is State Street Custodial Services (Ireland) Limited. Further information about the Company and the Fund including the prospectus and most recent annual reports and semi-annual reports is available free of charge online at www.vaneck.com or on request at the registered office of the company. These documents are available in English and certain other languages. The Fund is a sub-fund of the Company, an umbrella fund structure comprising different sub-funds. This document is specific to the Fund stated at the beginning of this document. However, the prospectus, annual and semi-annual reports are prepared for the Company rather than separately for the Fund.
The net asset value and other information is available online at www.vaneck.com. Investors can buy or sell shares daily on stock exchange(s) on which the shares are traded. The Fund shares are traded on one or more stock exchanges.
The details of the remuneration policy of the management company, VanEck Asset Management B.V., including, but not limited to, a description of how remuneration benefits are calculated, the identities of persons responsible for awarding the remuneration and benefits including the composition of the remuneration committee, where applicable, may be obtained from the website www.vaneck.com and a paper copy is available, free of charge and upon request, at the registered office of the management company. The Company is subject to the tax laws and regulations of Ireland. Depending on your own country of residence, this may have an impact on your investment. Please consult your investment or tax adviser for advice on your own tax liabilities.
Further details regarding the Index are available on the Index Provider's website: www.marketvector.com
VanEck Asset Management B.V. may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus of the Fund.
Under Irish law, the Company has segregated liability between its sub-funds. The Fund's assets will not be used to discharge the liabilities of other sub-funds of the Company. In addition, the Fund's assets and liabilities are segregated and held separately from the assets of other sub-funds.

The Fund is authorized in Ireland and regulated by the Central Bank of Ireland (CBI). VanEck Asset Management B.V. is authorized in the Netherlands and regulated by the Dutch Authority for the Financial Markets (AFM). The key investor information is accurate as at 18 February 2026.